Differential effects of ketoconazole, itraconazole and voriconazole on the pharmacokinetics of imatinib and its main metabolite GCP74588 in rat

Pharmacokinetic interaction study between quercetin and valsartan in rats andin vitromodels

(2012) Venkatesh R. Challa et al.   DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY

Influence of quercetin on the pharmacokinetics of ranolazine in rats andin vitromodels

(2012) P. Ravindra Babu et al.   DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY

Switching from intravenous to oral tacrolimus and voriconazole leads to a more pronounced drug–drug interaction

(2012) Isabel Spriet et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects

(2011) Bimal Malhotra et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor

(2011) Paul Hamberg et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations

(2011) Tiina Karonen et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacogenomics of the triazole antifungal agent voriconazole

(2011) Gerd Mikus et al.   PHARMACOGENOMICS

Therapeutic Drug Monitoring of Voriconazole and Posaconazole

(2011) Trana Hussaini et al.   PHARMACOTHERAPY

Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes

(2011) Shimin Zhang et al.   XENOBIOTICA

Accurate Prediction of Dose-Dependent CYP3A4 Inhibition by Itraconazole and Its Metabolites From In Vitro Inhibition Data

(2010) I Templeton et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone

(2010) Oliver Kummer et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Itraconazole, a P-Glycoprotein and CYP3A4 Inhibitor, Markedly Raises the Plasma Concentrations and Enhances the Renin-Inhibiting Effect of Aliskiren

(2010) Tuija Tapaninen et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents

(2009) Roger J. M. Brüggemann et al.   CLINICAL INFECTIOUS DISEASES

Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: A randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers

(2009) Susana Parrillo-Campiglia et al.   CLINICAL THERAPEUTICS

Reduced exposure of imatinib after coadministration with acetaminophen in mice

(2009) Ignacio Segarra et al.   INDIAN JOURNAL OF PHARMACOLOGY

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

(2008) R. A. Larson et al.   BLOOD

Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia

(2008) Yanfeng Wang et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY